Search

This document provides a list of drugs associated with non-serious adverse events identified in scientific literature over the past week. The table includes the drug names, the adverse events, and the number of cases reported. Some examples of adverse events include alopecia areata associated with Adalimumab, injection site reactions associated with Anakinra, and abdominal pain and flushing associated with Carbetocin and Oxytocin. It is important to note that these adverse events are non-serious and may not represent the overall safety profile of these drugs. [Extracted from the article]

A case report published in Reactions Weekly described a patient who developed urinary retention during treatment with dexmedetomidine and nalbuphine for postoperative pain following endoscopic sinus surgery. The patient received preventive analgesia with dexmedetomidine and nalbuphine prior to anesthesia induction, which led to the development of urinary retention. The event occurred in a randomized controlled trial involving 90 patients between May 2022 and December 2022, highlighting a potential adverse effect of this analgesic combination. [Extracted from the article]

A case report in the journal Reactions Weekly describes a 31-year-old man who developed enterovirus radiculomyelitis while being treated with ocrelizumab for multiple sclerosis. The man presented with various symptoms, including headache, fever, nausea, vomiting, back pain, and urinary retention, followed by bilateral leg weakness. MRI findings showed spinal cord abnormalities, and further testing confirmed the presence of enterovirus in his system. Treatment with immune-globulin, fluoxetine, and steroids led to a steady improvement in his condition, allowing him to regain independent ambulation within a week. [Extracted from the article]

A 70-year-old man developed extramedullary haematopoiesis while being treated with luspatercept for myelodysplastic syndrome. He experienced worsening bilateral leg weakness, urine retention, and bilateral patella hyperreflexia. MRI revealed soft tissue masses in the epidural space compressing his spinal cord, leading to T5-10 laminectomy. Biopsy confirmed the extramedullary haematopoiesis was a result of luspatercept treatment. [Extracted from the article]

A 79-year-old man experienced treatment failure with tamsulosin for postoperative urinary retention following the Vertiflex procedure. Despite a history of cerebrovascular accident, hypercholesterolaemia, diabetes, and lumbar spinal stenosis, the man underwent successful implant placement but developed urinary retention post-procedure. Treatment with tamsulosin and pelvic floor physical therapy sessions did not resolve the issue, leading to detrusor-sphincter dyssynergia (DSD) confirmation. [Extracted from the article]

A 53-year-old man experienced acute urinary retention while being treated with ipratropium-bromide/salbutamol for severe asthma exacerbation. Despite a history of multiple intubations, he was admitted to the ICU for management and received non-invasive positive pressure ventilation. The man's ICU stay was complicated by the development of acute urinary retention, requiring urinary catheter insertion. After switching to salbutamol, his urinary issues resolved, and he was discharged with the catheter in place, which was later successfully removed during a follow-up appointment. [Extracted from the article]

A 51-year-old woman experienced acute urinary retention while being treated with sertraline, and her urinary symptoms worsened with escitalopram and olanzapine for depression with melancholic features. She had a history of neurological bladder and high blood pressure, and after various treatments, including a suprapubic catheter, her symptoms improved. Ultimately, she was treated with paroxetine, quetiapine, and oxazepam for her psychiatric symptoms. [Extracted from the article]

A 33-year-old man experienced urinary retention while being treated with venlafaxine for a severe depressive episode. The patient had a history of depression and was initially prescribed a dose of 75mg/d, which was later increased to 112.5mg/d for four weeks. However, the increased dose led to urinary retention. Upon the recommendation of a urologist, the dose was reduced back to 75mg/d, resulting in significant improvement in urinary symptoms. The patient was then switched to mirtazapine and underwent cognitive-behavioral therapy for nine months, ultimately resolving the urinary retention issue. [Extracted from the article]

In a case report published in Reactions Weekly, a patient undergoing urologic surgery developed postoperative acute urinary retention (PAUR) while being treated with ropivacaine. The patient received ropivacaine 0.5% 2 mL/h during the surgery, but experienced PAUR afterwards. The specific details of the patient's age, sex, route of administration, duration of treatment, and outcome were not provided in the report. This case highlights a potential adverse reaction associated with ropivacaine use in urologic surgery. [Extracted from the article]

An elderly woman developed a spontaneous major extradural hematoma while being treated with ibrutinib for splenic marginal zone lymphoma. She initially presented with low back pain, followed by urinary retention and acute compressive myelopathy. MRI revealed the presence of extradural hemorrhage. Further investigations confirmed that the hematoma was a result of the ibrutinib treatment. The duration of treatment and outcome were not specified in the report. [Extracted from the article]

A 71-year-old man developed a spinal epidural hematoma while being treated for rheumatic heart disease with acenocoumarol, paracetamol, and ranitidine. He experienced symptoms such as acute painful retention of urine, numbness in the soles, weakness in the lower limbs, and a tight band-like sensation in the upper back and trunk. The man's MRI showed an epidural hematoma at the D3-D8 level, and it was confirmed that the hematoma was caused by the medications he was taking. He was treated with vitamin K, steroids, and his condition improved, with a significant reduction in the size of the hematoma. [Extracted from the article]

A 54-year-old man experienced acute kidney injury due to acute urinary retention while being treated with paracetamol/dextromethorphan/chlorphenamine/pseudoephedrine for cough and sputum. His medical history included heart failure, atrial fibrillation, gout, and a right calcaneal fracture. The man's symptoms improved after discontinuing the medication, and he was discharged with furosemide and sacubitril/valsartan. At follow-up, all symptoms had resolved, including the acute urinary retention and acute kidney injury. [Extracted from the article]

A 15-year-old boy experienced acute urinary retention and bilateral mydriasis due to dextromethorphan toxicity after intentionally overdosing on the drug in a suicide attempt. He presented with inability to urinate for 16 hours, a distended abdomen, and bilateral mydriasis. The boy admitted to ingesting 12 tablets of dextromethorphan (total 240 mg) voluntarily. The case was considered a result of dextromethorphan toxicity following an intentional overdose. [Extracted from the article]

A case report published in Reactions Weekly describes a 72-year-old man who exhibited lack of efficacy during treatment with ampicillin for an Aerococcus urinae infection. The man initially presented to the emergency room with lethargy and unresponsiveness, and subsequently developed urinary retention, shock, and acute cystitis. Despite receiving treatment with ampicillin, his infection was complicated by myocardial infarction, infectious endocarditis, paraaortic abscess, and an aortoatrial fistula. Unfortunately, the patient ultimately died, indicating a lack of efficacy of ampicillin in treating his infection. [Extracted from the article]

An 18-year-old man experienced vocal cord paralysis, lower extremity neuropathy, and urinary retention while being treated with vincristine for early T-cell precursor acute lymphoblastic leukemia. The man initially presented with symptoms such as lower limb swelling, fatigue, and nose bleeds. After investigations, he was diagnosed with early T-cell precursor acute lymphoblastic leukemia and ataxia telangiectasia. Vincristine was stopped, and venetoclax was added to his treatment, which he tolerated well. He is currently in remission four months after therapy with venetoclax. [Extracted from the article]

A 71-year-old woman with rheumatoid arthritis developed multi-dermatomal herpes zoster while being treated with methotrexate, leflunomide, and upadacitinib. She presented with a painful rash and mild fever and was admitted to the hospital. Bacterial cellulitis was also noted. She was treated with antibiotics, antivirals, and pain medication. She experienced acute urinary retention and constipation, which were considered secondary to the herpes zoster. After treatment, her symptoms improved and she was discharged with a temporary catheter. At a follow-up appointment, her bladder function had recovered. [Extracted from the article]

A case report from the urology department of Hangzhou third people's hospital describes a patient who developed urinary retention during treatment with botulinum-toxin-A for overactive bladder. The patient, whose age and sex were not stated, received injections of botulinum-toxin-A at a concentration of 10U/ml. However, the urinary retention was relieved after catheterization. This retrospective study highlights a potential adverse effect of botulinum-toxin-A treatment for overactive bladder. [Extracted from the article]

A 62-year-old woman experienced acute urinary retention and lack of efficacy during treatment with multiple drugs while undergoing general anesthesia for a forearm fracture surgery. The drugs involved were glycopyrrolate, fentanyl, propofol, atracurium-besilate, and mephentermine. The patient's blood pressure and heart rate fluctuated during the procedure, and she required norepinephrine to stabilize her blood pressure. After the surgery, it was discovered that the urinary retention was caused by the combination of glycopyrrolate, fentanyl, propofol, and atracurium-besilate. The issue was resolved with a saline flush, and the patient recovered without further complications. [Extracted from the article]

A retrospective cohort study examined 186 patients who were treated with topiramate, oxcarbazepine, clobazam, or phenytoin for seizures. The study found that some patients experienced side effects such as sleepiness, rash, kidney stones, or urine retention. The patients in the study had seizures with trisomy-18 and received anti-seizure treatment with one of the mentioned drugs. The side effects varied depending on the drug, with sleepiness and rash being common. [Extracted from the article]

A 66-year-old man experienced acute urinary retention and acute kidney injury after taking midodrine and gabapentin together. He was being treated for hepatorenal syndrome and neuropathic pain. Despite receiving treatment, his condition did not improve, and his kidney function worsened. The man's symptoms improved after the medications were stopped, suggesting that the interaction between midodrine and gabapentin caused his urinary retention and kidney injury. [Extracted from the article]

A 56-year-old man with schizophrenia developed hyponatremia while being treated with multiple drugs including clomipramine, haloperidol, clotiapine, quetiapine, fluphenazine, and clonazepam. He experienced symptoms such as disorganized behavior, agitation, hallucinations, ataxia, vomiting, and urinary retention. After water restriction, his symptoms improved and he was discharged, but he was readmitted multiple times with the same symptoms. The man's medication was changed to clozapine, which resolved his hyponatremia. The endocrinology team did not classify this episode as SIADH due to borderline blood and urine values. [Extracted from the article]

A 56-year-old man with schizophrenia developed hyponatremia while being treated with multiple drugs including clomipramine, haloperidol, clotiapine, quetiapine, fluphenazine, and clonazepam. He experienced symptoms such as disorganized behavior, agitation, hallucinations, ataxia, vomiting, and urinary retention. After water restriction, his symptoms improved and he was discharged, but he was readmitted multiple times with the same symptoms. The man's medication was changed to clozapine, which resolved his hyponatremia. The endocrinology team did not classify this episode as SIADH due to borderline blood and urine values. [Extracted from the article]

A man in his 70s developed urinary retention and constipation while being treated with imipramine for cenesthopathy. The man had a history of ischaemic disease, hypertension, and diabetes mellitus, and was receiving unspecified treatment. After starting imipramine, he experienced urinary retention and constipation, leading him to discontinue the medication. At the age of 77, he began experiencing bizarre sensations in his teeth and tongue, and vortioxetine was prescribed to alleviate these symptoms. [Extracted from the article]

A 17-month-old boy developed haemorrhagic cystitis while being treated with cyclophosphamide for bladder/prostate rhabdomyosarcoma. The boy had received chemotherapy and radiation therapy, which resulted in a reduction of the tumor mass but also caused persistent urinary retention. After completing radiation therapy, he developed grade-1 haemorrhagic cystitis as a side effect of the cyclophosphamide treatment. No other complications were reported during the follow-up period. [Extracted from the article]

This article describes four case reports of patients who experienced adverse effects from various medications. In the first case, a 54-year-old man with depression developed neuroleptic malignant syndrome (NMS) after taking sulpiride, perphenazine, and other medications. The second case involved a 55-year-old man with schizophrenia who experienced urinary retention due to haloperidol. The third case involved a 74-year-old woman with bipolar disorder who did not respond to multiple antidepressant medications. The fourth case involved a 68-year-old woman with schizophrenia who developed pseudoaldosteronism from taking glycyrrhizin and licorice. These case reports highlight the potential lack of efficacy and various toxicities associated with certain medications. [Extracted from the article]

This article discusses four case reports of patients with gastric adenocarcinoma who experienced various toxicities and lack of efficacy while receiving immunotherapies. The patients, aged between 67 and 76 years, developed symptoms such as fever, immune-related myocarditis, shivering, urinary retention, and erythra during treatment with nivolumab, ipilimumab, trastuzumab, or sintilimab. One patient also showed lack of efficacy despite receiving sintilimab and ipilimumab. All four patients underwent surgery after experiencing these complications. It is important for researchers and medical professionals to be aware of these potential side effects when considering immunotherapy for gastric adenocarcinoma. [Extracted from the article]

A 63-year-old man developed spontaneous haematomyelia while being treated with rivaroxaban for atrial fibrillation. He experienced weakness and impaired sensation in his left lower leg, along with urinary retention. Physical examination revealed motor weakness and impaired sensation in the left leg, and MRI scans confirmed the presence of an acute hemorrhage in the spinal cord. The man discontinued rivaroxaban and received methylprednisolone pulse therapy, which led to significant improvement in his symptoms. After three months, he experienced a complete recovery with no signs of haematomyelia. [Extracted from the article]

A case report published in Reactions Weekly describes the toxicities experienced by a 16-year-old girl following an intentional overdose and misuse of loperamide. The girl, who had anorexia nervosa, initially presented with symptoms such as dizziness, syncope, constipation, and weight loss. Despite her weight being restored, her symptoms worsened, and she developed postural orthostatic tachycardia syndrome (POTS). The girl eventually developed acute urinary retention and required hospitalization. It was determined that her symptoms were caused by chronic surreptitious high-dose loperamide use, and her symptoms rapidly improved after discontinuing loperamide therapy. [Extracted from the article]

A 46-year-old man developed monkeypox virus infection and lymphopenia while being treated with fingolimod for relapsing-remitting multiple sclerosis (MS). The man had controlled MS and had been taking fingolimod for a long time. He developed painful skin lesions and tests revealed monkeypox virus infection. He also experienced various other symptoms, including gastrointestinal bleeding, lymphadenopathy, and urinary retention. Fingolimod was discontinued and the man's condition improved with supportive treatment. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a prospective, observational study of 504 adult patients with overactive bladder (OAB) symptoms, an adult patient [ I exact age and sex not stated i ] was described, who developed urinary retention during treatment with botulinum-toxin-A for OAB symptoms. The patient, who had OAB symptoms was previously treated with unspecified oral medication and was refractory. However, the patient developed severe urinary retention secondary to botulinum-toxin-A [ I duration of treatment to reaction onset and outcome not state i d]. [Extracted from the article]